Health experts are seeing signs of a much smaller wave of U.S. COVID-19 cases this winter than in previous years, which could ...

U.S. health experts anticipate a smaller wave of COVID-19 cases this winter, potentially impacting Pfizer's non-COVID ...

Wen Shuhao helped speed up the development of Pfizer’s Covid oral drug, Paxlovid. Now the chairman of Xtalpi wants to help ...

The pharmaceutical giant Pfizer will pay nearly $60 million to resolve charges that a company it acquired paid kickbacks so ...

Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.

PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the ...

Paxlovid vs placebo reduced COVID-19-related hospitalization and death due to any cause through 28 days, as well as the duration of COVID-19 symptoms.

We recently compiled a list of the 12 Best Long Term Low Risk Stocks to Buy Right Now. In this article, we are going to take ...

The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.

Pfizer (NYSE:PFE – Get Free Report) had its price objective decreased by equities research analysts at Citigroup from $30.00 ...

Are those fears warranted? Pfizer benefited from the pandemic. Sales of its COVID-19 vaccine (Comirnaty) and treatment (Paxlovid) totaled over $56 billion in 2022, over half of the company's ...